ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma

K. Sasaki1, J. McVey1, D. Firl2, Y. Inaba3, C. D. Kwon1, K. Hashimoto1, F. Aucejo1

1The Cleveland Clinic, Cleveland, OH, 2Duke University, Durham, NC, 3Chiba University, Chiba, Japan

Meeting: 2020 American Transplant Congress

Abstract number: B-146

Keywords: Hepatocellular carcinoma, Immunosuppression

Session Information

Session Name: Poster Session B: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver. The recurrence of HCC after LT has mainly two sources, 1) growing pre-transplant existing tumor or 2) migration of circulating tumor after LT. Inevitable immunosuppression after LT promotes both causes of tumor recurrence. Although postoperative immunosuppression level is the only modifiable factor to prevent HCC recurrence after LT, optimal immunosuppression management strategy after LT for HCC is still unknown.

*Methods: 524 patients were involved, and time-weighted average (TWA) tacrolimus level at 1-, 3-, and 6-months after LT were collected. The time-dependent competing risk ROC analysis was performed to investigate the best time point and cut-off level to predict recurrence. The hazard ratios (HRs) of tumor recurrence, according to the level of tacrolimus, were estimated using Fine-Gray model competing risk regression. The risk of immunosuppression was adjusted with history of rejection, induction therapy, and tumor/patient factors.

*Results: : Recurrence was seen in 74 patients, and 117 patients died without recurrence. The median TWA tacrolimus levels at 1-, 3-, and 6-months after LT were 9.4, 8.7, and 8.4, respectively. The time-dependent AUCs were plotted in Figure A, demonstrating 3 months TWA had the highest AUC to predict recurrence (0.63). The cut-off of 3 months TWA tacrolimus level was 8.7, according to Youden index. The graft rejection confirmed by biopsy within 3 months after LT was seen in 33 patients. The median TWA tacrolimus level was significantly higher in patients who had rejection (9.8 vs 8.6). The cumulative recurrence rate in patients with 3 months TWA tacrolimus < 8.7 was significantly low and the same trend was seen even after two years from LT (Figure B and C). The 5—year survival was also significantly better in lower tacrolimus patients (Figure D). Patients with lower tacrolimus had significantly low HRs of tumor recurrence as 0.55 (031-0.96).

*Conclusions: Lower tacrolimus level (<8.7) was strongly associated with lower risk of recurrence and better 5-year survival. External validation is needed to confirm this finding.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sasaki K, McVey J, Firl D, Inaba Y, Kwon CD, Hashimoto K, Aucejo F. The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-oncological-optimal-tacrolimus-target-level-after-liver-transplant-for-hepatocellular-carcinoma/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences